The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.

scientific article published on August 2006

The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1538-7836.2006.02045.X
P698PubMed publication ID16879211
P5875ResearchGate publication ID6907843

P50authorBruce M. PsatyQ30429993
Jcm MeijersQ68093274
Susan R HeckbertQ88077554
Thomas LumleyQ102228619
P2093author name stringRosendaal FR
Reiner AP
Smith NL
Doggen CJ
Lemaitre RN
P2860cites workRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialQ27860743
Pharmacokinetic and pharmacologic variation between different estrogen productsQ28271356
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over studyQ28368332
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trialQ29615226
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research GroupQ29615228
The pharmacokinetics and efficacy of different estrogens are not equivalentQ32067302
Mutation in blood coagulation factor V associated with resistance to activated protein C.Q34340007
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosisQ34356168
Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolismQ34451410
Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal womenQ38504402
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factorsQ42646583
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trialQ43795711
Replacing short-acting nifedipine with alternative medications at a large health maintenance organizationQ43882432
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal womenQ44242587
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal womenQ44429143
Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric StudyQ44472887
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trialQ44517324
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled studyQ44666769
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetateQ45154446
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studiesQ45197770
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramideQ46470688
Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly womenQ46594043
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and womenQ47741055
Determinants of the APTT- and ETP-based APC sensitivity tests.Q53853713
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectactivated protein C resistanceQ296104
drotrecogin alfaQ412888
P304page(s)1701-1706
P577publication date2006-08-01
P1433published inJournal of Thrombosis and HaemostasisQ6296004
P1476titleThe differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women
P478volume4

Reverse relations

cites work (P2860)
Q55982498Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women
Q37727617Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers
Q28607716Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens
Q37238147Venous thromboembolism in women

Search more.